Table 3. Association with 30-day mortality for subgroups unmatched and matched for propensity.
| Clinical outcome | Unmatched | Propensity matched | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Macrolide exposure | OR (95% CI) | P value | Macrolide exposure | OR (95% CI) | P value | ||||
| No | Yes | No | Yes | ||||||
| 30-day mortality | |||||||||
| Non-pulmonary ARDS | 32.1% (n=290) | 21.1% (n=76) | 0.56 (0.31–1.03) | 0.06 | 33.8% (n=195) | 21.1% (n=76) | 0.50 (0.26–0.95) | 0.04 | |
| Pulmonary ARDS | 31.3% (n=425) | 24.4% (n=82) | 0.71 (0.41–1.22) | 0.21 | 30.5% (n=279) | 24.4% (n=82) | 0.71 (0.39–1.27) | 0.25 | |
| Phenotype I | 22.7% (n=251) | 8.8% (n=45) | 0.23 (0.07–0.73) | 0.01 | 24.8% (n=165) | 8.8% (n=45) | 0.20 (0.06–0.65) | <0.01 | |
| Phenotype II | 41.3% (n=254) | 32.4% (n=71) | 0.76 (0.41–1.44) | 0.04 | 42.3% (n=163) | 32.4% (n=71) | 0.74 (0.40–1.38) | 0.34 | |
P value and OR for association of macrolide use and 30-day mortality. CI, confidence interval; OR, odds ratio; ARDS, acute respiratory distress syndrome.